Importantly, the gemfibrozil and gemfibrozil acyl glucuronide have been shown to inhibit organic anion transporter protein (OATP1B1) and organic anion transporter 3 (OAT3), which may affect the pharmacokinetics and transport of their substrates that include glimepiride, nateglinide, sitagliptin, empagliflozin, as well as repaglinide used in the treatment of type-2 diabetes, paritaprevir used as an anti-HIV drug, and several statins including simvastatin, lovastatin, pravastatin, pitavastatin, atorvastatin, and rosuvastatin [11,12,28,29,30,31]. Here, SLC22A8 is linked to type 2 diabetes mellitus.